Compare DINO & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DINO | KRYS |
|---|---|---|
| Founded | 1947 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7B | 7.8B |
| IPO Year | N/A | 2017 |
| Metric | DINO | KRYS |
|---|---|---|
| Price | $58.48 | $274.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 11 |
| Target Price | $59.50 | ★ $257.45 |
| AVG Volume (30 Days) | ★ 2.3M | 249.5K |
| Earning Date | 02-18-2026 | 02-17-2026 |
| Dividend Yield | ★ 3.42% | N/A |
| EPS Growth | 21.43 | ★ 275.72 |
| EPS | 2.07 | ★ 6.66 |
| Revenue | ★ $26,905,000,000.00 | $373,164,000.00 |
| Revenue This Year | N/A | $36.13 |
| Revenue Next Year | $0.11 | $41.52 |
| P/E Ratio | ★ $28.29 | $41.50 |
| Revenue Growth | N/A | ★ 54.51 |
| 52 Week Low | $24.66 | $122.80 |
| 52 Week High | $59.33 | $295.98 |
| Indicator | DINO | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 67.13 | 57.43 |
| Support Level | $56.74 | $264.85 |
| Resistance Level | $59.33 | $280.00 |
| Average True Range (ATR) | 1.57 | 10.17 |
| MACD | 0.46 | -1.91 |
| Stochastic Oscillator | 81.11 | 70.94 |
HF Sinclair is an integrated petroleum refiner that owns and operates seven refineries serving the Rockies, midcontinent, Southwest, and Pacific Northwest, with a total crude oil throughput capacity of 678,000 barrels per day. It can produce 380 million gallons of renewable diesel annually. It holds a marketing business with over 300 distributors and 1,500 wholesale branded sites across 30 states. It also owns and operates 4,400 miles of petroleum product pipelines and terminals principally in the southwestern United States.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.